Article Impact Level: HIGH Data Quality: STRONG Summary of Cell Reports https://doi.org/10.1016/j.celrep.2025.116574 Dr. Jennifer N. Luck et al.
Points
- Genome-wide association studies identified the ZmpB enzyme as the primary factor allowing Streptococcus pneumoniae to invade heart tissue and cause severe cardiac complications in patients.
- Mice infected with bacterial strains lacking the ZmpB gene exhibited significantly fewer cardiac microlesions and reduced cell death compared to those infected with wild-type pneumonia strains.
- The study determined that the presence of specific FIVAR domains on the ZmpB enzyme directly correlates with the ability of bacteria to penetrate and survive within cardiomyocytes.
- Human cardiac organoids exposed to bacteria without these specific domains showed maintained contractility and lower rates of tissue damage during in vitro experimental testing.
- Immunization with recombinant ZmpB provided protective immunity in animal models which suggests this enzyme could serve as a target for future preventative vaccines against heart damage.
Summary
This study investigated the pathogenesis of adverse cardiac events, which affect approximately one in five patients hospitalized with pneumonia and significantly increase the long-term risk of heart failure. Utilizing bacterial genome-wide association studies (bGWAS), researchers identified the zinc metalloprotease B (ZmpB) enzyme as a critical determinant in Streptococcus pneumoniae-mediated cardiac damage. The analysis specifically linked strains possessing ZmpB with distinctive FIVAR (found in various architectures) domains to an increased capacity for invading and surviving within heart tissue, leading to the formation of damaging microlesions.
In murine models, subjects infected with ZmpB-deficient S. pneumoniae exhibited significantly reduced cardiac microlesions and cell death compared to those infected with wild-type strains. Further validation using human induced pluripotent stem cell (iPSC)-derived 3D cardiac organoids demonstrated that ZmpB-deficient bacteria were attenuated in their ability to impair contractility, invade cells, and survive intracellularly. The research highlighted a dose-dependent relationship regarding FIVAR domains; variants rich in these domains at the N-terminus were prevalent in clinical isolates associated with severe human cardiac complications, whereas those lacking them showed reduced pathogenicity.
Immunization with recombinant ZmpB in mouse models conferred protection against cardiac damage, establishing the enzyme as a viable therapeutic target. The findings suggest that the specific allele and architecture of the ZmpB gene function as molecular fingerprints for high-risk strains. This discovery supports the potential development of genetic screening protocols to identify patients requiring intensified cardiac monitoring and paves the way for novel vaccine strategies aimed at neutralizing the invasive capacity of S. pneumoniae to prevent long-term cardiovascular sequelae.
Link to the article: https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01346-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124725013464%3Fshowall%3Dtrue
References
Luck, J. N., D’Mello, A., Chembilikandy, V., Lane, J. R., Kruckow, K., Martínez, E., Rodriguez, E., Mohasin, M., Berg, I., Porter, K. D., Sethu, P., Tettelin, H., & Orihuela, C. J. (2025). Allele-specific zinc metalloprotease B influences cardiac damage during invasive pneumococcal disease. Cell Reports, 116574. https://doi.org/10.1016/j.celrep.2025.116574
